$PBIO Pressure BioSciences' $3.5 Million Order for
Post# of 40256
(Total Views: 206)
Posted On: 06/16/2020 9:14:00 AM
$PBIO Pressure BioSciences' $3.5 Million Order for Hand Sanitizer is a Major Indicator for Growth
South Easton, Massachusetts--(Newsfile Corp. - June 12, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was the recent subject of an article by leading publisher Small Caps Daily, concerning their latest announcement of a $3.5 million order for hand sanitizers amid the ongoing global COVID-19 pandemic.
Recently, PBIO merged with CannawoRx, a company which has a strong and diversified portfolio of U.S. hemp-derived CBD products and intellectual property developed by its founders, Dr. Bobby Ghalili and Dr Adrienne Denese, who are medical and product development experts. In addition, PBIO announced a simultaneous acquisition of Dr. Denese's acclaimed SkinScience® brand, which is a profitable and highly renowned company within the cosmetics space. SkinScience has generated approximately $18 million in revenue in 2019 alone and over $500 million over the past 17 years. The brand has sold over 25 million units and has won many customer choice beauty awards over the years.
SkinScience, a prominent name in the cosmeceutical industry, sought to address an inadequately met need amid the acute shortage of hand sanitizer as reported by numerous retail outlets. The Company developed, manufactured and began distributing a premium, dermatologically-focused hand sanitizer, and secured a large initial order based on its loyal and global customer base.
Key Takeaways
? The SkinScience hand sanitizer, was a proprietary formula developed by founder Dr. Adrienne Denese, MD., Ph.D, who is a skilled scientist, physician and a visionary in the skin care market. The formula is less harsh on human skin, focusing on the dermatologic benefits and utilizing a relatively low, alcohol content.
? The $3.5 Million order of hand sanitizer, is a four month-supply, for just one customer; this large initial order, coupled with the increased demand for hand sanitizers as the world navigates through the pandemic and beyond, denotes an impressive forecast for 2020.
? The global hand sanitizer market is estimated at $5.5 billion and is expected to grow at an annualized rate of 22.7% over the next 5 years. The US continues to be the largest market for hand sanitizers and the demand for these products has increased during each of the public health epidemics since the SARS outbreak in 2003, H5N1 Avian influenza in 2006, and the 2009 outbreak of swine flu.
? PBIO benefits from the $3.5 Million order, through its acquisition of SkinScience. The entity resulting from the merger of CannawoRx and SkinScience will be known as Availa Bio and is will operate as a conglomerate, owning 31 patents and catering to multiple and varied markets such as pressure-based instruments, biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and many more.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST" platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
South Easton, Massachusetts--(Newsfile Corp. - June 12, 2020) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, was the recent subject of an article by leading publisher Small Caps Daily, concerning their latest announcement of a $3.5 million order for hand sanitizers amid the ongoing global COVID-19 pandemic. Recently, PBIO merged with CannawoRx, a company which has a strong and diversified portfolio of U.S. hemp-derived CBD products and intellectual property developed by its founders, Dr. Bobby Ghalili and Dr Adrienne Denese, who are medical and product development experts. In addition, PBIO announced a simultaneous acquisition of Dr. Denese's acclaimed SkinScience® brand, which is a profitable and highly renowned company within the cosmetics space. SkinScience has generated approximately $18 million in revenue in 2019 alone and over $500 million over the past 17 years. The brand has sold over 25 million units and has won many customer choice beauty awards over the years.
SkinScience, a prominent name in the cosmeceutical industry, sought to address an inadequately met need amid the acute shortage of hand sanitizer as reported by numerous retail outlets. The Company developed, manufactured and began distributing a premium, dermatologically-focused hand sanitizer, and secured a large initial order based on its loyal and global customer base.
Key Takeaways
? The SkinScience hand sanitizer, was a proprietary formula developed by founder Dr. Adrienne Denese, MD., Ph.D, who is a skilled scientist, physician and a visionary in the skin care market. The formula is less harsh on human skin, focusing on the dermatologic benefits and utilizing a relatively low, alcohol content.
? The $3.5 Million order of hand sanitizer, is a four month-supply, for just one customer; this large initial order, coupled with the increased demand for hand sanitizers as the world navigates through the pandemic and beyond, denotes an impressive forecast for 2020.
? The global hand sanitizer market is estimated at $5.5 billion and is expected to grow at an annualized rate of 22.7% over the next 5 years. The US continues to be the largest market for hand sanitizers and the demand for these products has increased during each of the public health epidemics since the SARS outbreak in 2003, H5N1 Avian influenza in 2006, and the 2009 outbreak of swine flu.
? PBIO benefits from the $3.5 Million order, through its acquisition of SkinScience. The entity resulting from the merger of CannawoRx and SkinScience will be known as Availa Bio and is will operate as a conglomerate, owning 31 patents and catering to multiple and varied markets such as pressure-based instruments, biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and many more.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the "BaroFold" technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST"
platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. 
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼